JP2019515899A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019515899A5 JP2019515899A5 JP2018553360A JP2018553360A JP2019515899A5 JP 2019515899 A5 JP2019515899 A5 JP 2019515899A5 JP 2018553360 A JP2018553360 A JP 2018553360A JP 2018553360 A JP2018553360 A JP 2018553360A JP 2019515899 A5 JP2019515899 A5 JP 2019515899A5
- Authority
- JP
- Japan
- Prior art keywords
- drug
- agent
- dose
- human subject
- therapeutically effective
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 19
- 229940079593 drug Drugs 0.000 claims 19
- 239000003795 chemical substances by application Substances 0.000 claims 10
- 210000001995 reticulocyte Anatomy 0.000 claims 6
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 claims 5
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 230000037452 priming Effects 0.000 claims 5
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims 4
- 108060003951 Immunoglobulin Proteins 0.000 claims 4
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims 4
- 102000018358 immunoglobulin Human genes 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 210000004369 blood Anatomy 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003978 infusion fluid Substances 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 claims 1
- 238000012292 receptor occupancy assay Methods 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022140214A JP7442591B2 (ja) | 2016-04-15 | 2022-09-02 | がん処置における抗ｃｄ４７薬の治療有効用量を決定及び達成する方法 |
| JP2024023723A JP2024059764A (ja) | 2016-04-15 | 2024-02-20 | がん処置における抗ｃｄ４７薬の治療有効用量を決定及び達成する方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662323330P | 2016-04-15 | 2016-04-15 | |
| US62/323,330 | 2016-04-15 | ||
| US201662427679P | 2016-11-29 | 2016-11-29 | |
| US62/427,679 | 2016-11-29 | ||
| PCT/US2017/027662 WO2017181033A1 (en) | 2016-04-15 | 2017-04-14 | Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022140214A Division JP7442591B2 (ja) | 2016-04-15 | 2022-09-02 | がん処置における抗ｃｄ４７薬の治療有効用量を決定及び達成する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019515899A JP2019515899A (ja) | 2019-06-13 |
| JP2019515899A5 true JP2019515899A5 (enExample) | 2020-05-14 |
| JP7532009B2 JP7532009B2 (ja) | 2024-08-13 |
Family
ID=60042716
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018553360A Active JP7532009B2 (ja) | 2016-04-15 | 2017-04-14 | がん処置における抗ｃｄ４７薬の治療有効用量を決定及び達成する方法 |
| JP2022140214A Active JP7442591B2 (ja) | 2016-04-15 | 2022-09-02 | がん処置における抗ｃｄ４７薬の治療有効用量を決定及び達成する方法 |
| JP2024023723A Pending JP2024059764A (ja) | 2016-04-15 | 2024-02-20 | がん処置における抗ｃｄ４７薬の治療有効用量を決定及び達成する方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022140214A Active JP7442591B2 (ja) | 2016-04-15 | 2022-09-02 | がん処置における抗ｃｄ４７薬の治療有効用量を決定及び達成する方法 |
| JP2024023723A Pending JP2024059764A (ja) | 2016-04-15 | 2024-02-20 | がん処置における抗ｃｄ４７薬の治療有効用量を決定及び達成する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11472878B2 (enExample) |
| EP (3) | EP3442578B1 (enExample) |
| JP (3) | JP7532009B2 (enExample) |
| KR (3) | KR20230035435A (enExample) |
| CN (3) | CN115350276A (enExample) |
| AU (2) | AU2017250809B2 (enExample) |
| CA (1) | CA3019676A1 (enExample) |
| ES (1) | ES2909835T3 (enExample) |
| PL (1) | PL3442578T3 (enExample) |
| PT (1) | PT3442578T (enExample) |
| SI (1) | SI3442578T1 (enExample) |
| WO (1) | WO2017181033A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3042583A1 (en) | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Improvements in cd47 blockade therapy by hdac inhibitors |
| KR102776457B1 (ko) | 2017-10-18 | 2025-03-06 | 포티 세븐, 엘엘씨 | 항-cd47 작용제-기초된 난소암 요법 |
| ES2927305T3 (es) | 2018-02-12 | 2022-11-04 | Forty Seven Inc | Régimen contra el cáncer usando anticuerpos anti-CD47 y anti-CD20 |
| GB201804860D0 (en) | 2018-03-27 | 2018-05-09 | Ultrahuman Two Ltd | CD47 Binding agents |
| EP3817769A4 (en) * | 2018-07-05 | 2022-03-30 | Trican Biotechnology Co., Ltd | Human anti-cd47 antibodies and uses thereof |
| BR112021005585A2 (pt) | 2018-09-27 | 2021-06-29 | Celgene Corporation | proteínas de ligação a sirpa e métodos de uso das mesmas |
| US11591390B2 (en) | 2018-09-27 | 2023-02-28 | Celgene Corporation | SIRP-α binding proteins and methods of use thereof |
| CR20210272A (es) | 2018-11-26 | 2021-07-14 | Forty Seven Inc | Anticuerpos humanizados contra c-kit |
| AU2019390394C1 (en) | 2018-11-28 | 2024-11-28 | Forty Seven, LLC | Genetically modified HSPCs resistant to ablation regime |
| US12441807B2 (en) | 2019-09-18 | 2025-10-14 | Lamkap Bio Alpha AG | Bispecific antibodies against CEACAM5 and CD3 |
| PE20230160A1 (es) | 2019-12-17 | 2023-02-01 | Pfizer | Anticuerpos especificos para cd47, pd-l1 y sus usos |
| NZ792999A (en) * | 2020-04-06 | 2025-08-29 | Univ Leland Stanford Junior | Antibody formulation |
| CA3194577A1 (en) * | 2020-10-09 | 2022-04-14 | Sonja SCHREPFER | Methods for triggering safety killing mechanisms using a cd47-sirp.alpha. blockade agent |
| WO2022140659A2 (en) | 2020-12-23 | 2022-06-30 | D-10 Therapeutics, Inc. | Anti-cd47 antibodies and uses thereof |
| JP2024503822A (ja) * | 2021-01-05 | 2024-01-29 | ナショナル インスティテュート オブ バイオロジカル サイエンシズ，ベイジン | Ｇｐｃ３及びｃｄ４７を標的とする二重特異性抗体 |
| WO2023002415A2 (en) * | 2021-07-20 | 2023-01-26 | Magenta Therapeutics, Inc. | Methods and compositions for anti-cd117 antibody drug conjugate (adc) treatment |
| EP4516807A1 (en) | 2023-08-28 | 2025-03-05 | Consorcio Centro de Investigación Biomédica en Red | Compositions for use in a method of providing improved hematopoietic stem cell engraftment |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3056515T (pt) | 2008-01-15 | 2019-07-19 | Univ Leland Stanford Junior | Métodos para manipulação da fagocitose mediada por cd47 |
| MX2010008696A (es) * | 2008-02-07 | 2010-08-30 | Amgen Inc | Composiciones de proteina estabilizadas. |
| HRP20170254T1 (hr) | 2010-05-14 | 2017-04-21 | The Board of Trustees of the Leland Stanford Junior University Office of the General Counsel | Humanizirana i kimerna monoklonska protutijela usmjerena na cd47 |
| EP3766511A1 (en) | 2012-01-17 | 2021-01-20 | The Board of Trustees of the Leland Stanford Junior University | High affinity sirp-alpha reagents |
| EP3578569A1 (en) | 2012-02-06 | 2019-12-11 | Inhibrx, Inc. | Cd47 antibodies and methods of use thereof |
| KR102276974B1 (ko) | 2013-02-06 | 2021-07-13 | 인히브릭스, 인크. | 비-혈소판 및 비-적혈구 세포 격감성 cd47 항체 및 이를 이용하는 방법 |
| JP6426693B2 (ja) * | 2013-03-15 | 2018-11-21 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 抗ｃｄ４７薬の処理上有効量を達成するための方法 |
| EP3495814A3 (en) | 2013-03-27 | 2019-07-17 | F. Hoffmann-La Roche AG | Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists |
| WO2014179132A1 (en) | 2013-04-29 | 2014-11-06 | The Board Of Trustees Of The Leland Stanford Junior University | Use of anti-cd47 agents to enhance immunization |
| EP3052119B1 (en) | 2013-10-01 | 2018-08-22 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Methods of modulating erythropoiesis with arginine vasopressin receptor 1b molecules |
| ES2728668T3 (es) | 2014-01-08 | 2019-10-28 | Univ Leland Stanford Junior | Terapia dirigida para el cáncer de pulmón de células pequeñas |
| US10626179B2 (en) * | 2014-06-08 | 2020-04-21 | Remd Biotherapeutics, Inc. | Methods for treating type 1 diabetes using glucagon receptor antagonistic antibodies |
| WO2016028810A1 (en) | 2014-08-18 | 2016-02-25 | Biogen Ma Inc. | Anti-cd40 antibodies and uses thereof |
| CA2964173A1 (en) * | 2014-10-10 | 2016-04-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods to eliminate cancer stem cells by targeting cd47 |
| NZ792999A (en) * | 2020-04-06 | 2025-08-29 | Univ Leland Stanford Junior | Antibody formulation |
-
2017
- 2017-04-14 EP EP17783254.0A patent/EP3442578B1/en active Active
- 2017-04-14 SI SI201731120T patent/SI3442578T1/sl unknown
- 2017-04-14 KR KR1020237006777A patent/KR20230035435A/ko not_active Ceased
- 2017-04-14 CN CN202210926503.6A patent/CN115350276A/zh active Pending
- 2017-04-14 PT PT177832540T patent/PT3442578T/pt unknown
- 2017-04-14 JP JP2018553360A patent/JP7532009B2/ja active Active
- 2017-04-14 CA CA3019676A patent/CA3019676A1/en active Pending
- 2017-04-14 US US16/089,115 patent/US11472878B2/en active Active
- 2017-04-14 EP EP24159469.6A patent/EP4349412A3/en active Pending
- 2017-04-14 AU AU2017250809A patent/AU2017250809B2/en active Active
- 2017-04-14 WO PCT/US2017/027662 patent/WO2017181033A1/en not_active Ceased
- 2017-04-14 CN CN201780029157.9A patent/CN109152837A/zh active Pending
- 2017-04-14 EP EP22155479.3A patent/EP4074339A1/en active Pending
- 2017-04-14 PL PL17783254T patent/PL3442578T3/pl unknown
- 2017-04-14 KR KR1020247002294A patent/KR20240016445A/ko active Pending
- 2017-04-14 KR KR1020187032126A patent/KR102505253B1/ko active Active
- 2017-04-14 CN CN202311544173.5A patent/CN117695387A/zh active Pending
- 2017-04-14 ES ES17783254T patent/ES2909835T3/es active Active
-
2022
- 2022-09-02 JP JP2022140214A patent/JP7442591B2/ja active Active
- 2022-09-08 US US17/930,621 patent/US11718670B2/en active Active
-
2023
- 2023-06-15 US US18/210,483 patent/US20230406923A1/en active Pending
-
2024
- 2024-02-20 JP JP2024023723A patent/JP2024059764A/ja active Pending
- 2024-05-22 AU AU2024203396A patent/AU2024203396A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019515899A5 (enExample) | ||
| Theiss et al. | Dual stem cell therapy after myocardial infarction acts specifically by enhanced homing via the SDF-1/CXCR4 axis | |
| von Haehling et al. | Ferric carboxymaltose and exercise capacity in heart failure with preserved ejection fraction and iron deficiency: the FAIR-HFpEF trial | |
| JP7125932B2 (ja) | 凝固第ｉｘ因子および／または活性化凝固第ｉｘ因子ならびに凝固第ｘ因子および／または活性化凝固第ｘ因子を認識する二重特異性抗体の使用法 | |
| JP2018515493A5 (enExample) | ||
| FI3227675T3 (fi) | Aktiviini-actrii-antagonisteja ja niiden käyttöjä myelodysplastisen oireyhtymän hoitamiseksi | |
| JP2012067116A5 (enExample) | ||
| JP2018535929A5 (enExample) | ||
| Qaiser et al. | Novel treatment pathways in pulmonary arterial hypertension | |
| JP6485970B2 (ja) | 自己免疫疾患の治療のための併用療法 | |
| JP2015013887A (ja) | アタシセプトなどのＴＡＣＩ−Ｉｇ融合タンパク質を用いた自己免疫疾患を治療するための投薬法 | |
| Patwardhan et al. | Biologics in refractory myositis: experience in juvenile vs. adult myositis; part II: emerging biologic and other therapies on the horizon | |
| Son et al. | SAMiRNA targeting amphiregulin alleviate total-body-irradiation-induced renal fibrosis | |
| Fragoso et al. | Emerging treatments and the clinical trial landscape for hidradenitis suppurativa part I: topical and systemic medical therapies | |
| JP2025148495A (ja) | Ｂ因子阻害剤の使用方法 | |
| JP2020510028A5 (enExample) | ||
| ES2935265T3 (es) | Método para tratar acontecimientos adversos inducidos por inhibidores de punto de control | |
| JPWO2022240688A5 (enExample) | ||
| WO2019241742A1 (en) | Combination of ezh2 inhibitor and checkpoint therapy for the treatment of cancer | |
| RU2014110271A (ru) | Восприимчивость к ингибиторам ангиогенеза | |
| Kumari et al. | Efficacy of therapeutic plasma exchange in a patient with coagulation inhibitors (acquired haemophilia A)–a case report | |
| CN112190708B (zh) | 趋化因子受体ccr6抑制剂在预防银屑病复发中的新应用 | |
| US20250019441A1 (en) | Treatment of cancer with anti-ilt2 antibodies | |
| JPWO2020219960A5 (enExample) | ||
| Haja | OC 8586 Institutional research capacity building for multi-disciplinary health research to support the health system rebuilding phase in sierra leone |